ReviewMolecules (Basel, Switzerland)2016
Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes.
Review in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed.
- Atomically Precise Polyanionic Boron Cluster Agents with Broad-Spectrum Antiviral Activity.Precision chemistry · 2026Article
- Green Synthesis of Silver Nanoparticles UsingMolecules (Basel, Switzerland) · 2026Article
- Smart nanosystems for disease-resistant potatoes: a new Frontier in nanobiotechnology.RSC advances · 2026Review
- Managing Bone Infections Beyond Systemic Antibiotics: A Scoping Review.Pathogens (Basel, Switzerland) · 2026Review
- Research Landscape and Emerging Trends in Herbal Medicine for Pediatric Respiratory Tract Infections: A CiteSpace-Based Bibliometric Analysis.Health science reports · 2026Article
- Plant-Based Nano-Delivery Systems in the Treatment of Inflammatory Disorders.Pharmaceutics · 2026Review
- Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistantFrontiers in pharmacology · 2026Review
- Antibacterial efficacy of iron oxide and silver nanoparticles against bacterial wilt pathogen Ralstonia solanacearum.Scientific reports · 2025Article
- Evaluation of the impact of synthesized carbon nanoparticles on extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: investigating antibacterial and cytotoxic properties.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Green synthesis of gamma rays-induced melanin-based bismuth oxide nanoparticles for evaluation of the antibacterial and anti-virulence activities against extra-intestinal pathogenic bacteria.World journal of microbiology & biotechnology · 2025Article
- Antibacterial activity of green-synthesized silver nanoparticles against Gram-negative bacteria and insights into potential resistance mechanisms.INNOSC theranostics & pharmacological sciences · 2025Article
- Review
- Recent Cutting-Edge Technologies for the Delivery of Peptide Nucleic Acid.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Review
- Bovine ocular microbiome: the next frontier in managing Pinkeye in cattle.Animal microbiome · 2025Article
- Antibacterial impact of biosynthesized zinc oxide nanoparticles on uropathogenic Escherichia coli and in vivo assessment of physiological and histological alterations.Scientific reports · 2025Article
- Article
- Comprehensive Overview of Antibacterial Drugs and Natural Antibacterial Compounds Found in Food Plants.Antibiotics (Basel, Switzerland) · 2025Review
- Nanocarriers: Exploring the Potential of Oligonucleotide Delivery.Current drug delivery · 2025Review
- Exploring Potential Use of Banana Peel Extract (Musa Species) as a New Polymer to Create Sustainable Materials and Innovative Drug Delivery Applications: An Updated Review.Recent advances in drug delivery and formulation · 2025Review
- Nanocarrier-based Delivery Approaches of Mangiferin: An Updated Review on Leveraging Biopharmaceutical Characteristics of the Bioactive.Current pharmaceutical biotechnology · 2025Review
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial substances may be synthetic, semisynthetic, or of natural origin (i.e., from plants and animals). Antimicrobials are considered "miracle drugs" and can determine if an infected patient/animal recovers or dies. However, the misuse of antimicrobials has led to the development of multi-drug-resistant bacteria, which is one of the greatest challenges for healthcare practitioners and is a significant global threat. The major concern with the development of antimicrobial resistance is the spread of resistant organisms. The replacement of conventional antimicrobials by new technology to counteract antimicrobial resistance is ongoing. Nanotechnology-driven innovations provide hope for patients and practitioners in overcoming the problem of drug resistance. Nanomaterials have tremendous potential in both the medical and veterinary fields. Several nanostructures comprising metallic particles have been developed to counteract microbial pathogens. The effectiveness of nanoparticles (NPs) depends on the interaction between the microorganism and the NPs. The development of effective nanomaterials requires in-depth knowledge of the physicochemical properties of NPs and the biological aspects of microorganisms. However, the risks associated with using NPs in healthcare need to be addressed. The present review highlights the antimicrobial effects of various nanomaterials and their potential advantages, drawbacks, or side effects. In addition, this comprehensive information may be useful in the discovery of broad-spectrum antimicrobial drugs for use against multi-drug-resistant microbial pathogens in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.